These data are also in line with earlier studies in which the potential of sGC stimulators was demonstrated in neuroinflammation (Correia et al. 2021b) and in preclinical models of neurodegenerative diseases (Correia et al. 2021a); sGC stimulators also improve mitochondrial function and cerebral blood flow (Buys et al. 2022, conference poster presented at this meeting). Here, SGCB is linked to neurodegenerative disease.